Why Moderna Stock Dove by Nearly 10% on Monday

1 min read

Though the FDA recently gave emergency use authorization (EUA) to Moderna‘s (NASDAQ: MRNA) mRNA-1273 coronavirus vaccine, the company’s stock was a big dud on Monday. This was likely due to some scary-sounding news regarding one patient who was administered the vaccine before Christmas.

The New York Times reported on Friday that Dr. Hossein Sadrzadeh, a geriatric oncology fellow at Boston Medical Center, said he developed a severe allergic reaction just after receiving his initial jab of mRNA-1273’s two-dose regimen.

Minutes after getting his shot, Sadrzadeh said he experienced dizziness and an increased heart rate. He was allowed to administer epinephrine to himself with an EpiPen, which he keeps on hand due to a severe shellfish allergy.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

Weibo Corporation (WB) Q3 2020 Earnings Call Transcript

Next Story

Merck and AstraZeneca’s Cancer Drug Wins 3 New Approvals in Japan

Latest from Blog